The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 13, 2018

Filed:

Jul. 23, 2013
Applicants:

Sylvie Hermouet, Nantes, FR;

Edith Bigot-corbel, Montfaucon-Montigné, FR;

Delphine Feron, Pont-Saint-Martin, FR;

Inventors:

Edith Bigot-Corbel, Nantes, FR;

Sylvie Hermouet, Nantes, FR;

Delphine Feron, Nantes, FR;

Cathy Charlier, Nantes, FR;

Pierre Weigel, Nantes, FR;

Adrien Herlédan, Lille, FR;

Yannick Jacques, Nantes, FR;

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/577 (2006.01); B01J 19/00 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/576 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/577 (2013.01); B01J 19/0046 (2013.01); G01N 33/56905 (2013.01); G01N 33/56922 (2013.01); G01N 33/56972 (2013.01); G01N 33/56994 (2013.01); G01N 33/5767 (2013.01); G01N 33/57426 (2013.01); G01N 33/6854 (2013.01); G01N 33/6893 (2013.01); G01N 2333/045 (2013.01); G01N 2333/05 (2013.01); G01N 2333/186 (2013.01); G01N 2333/205 (2013.01); G01N 2333/45 (2013.01); G01N 2800/22 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01);
Abstract

The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.


Find Patent Forward Citations

Loading…